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Effect of dietary n–3 polyunsaturated fatty acids on plasma total and
high-molecular-weight adiponectin concentrations in overweight to
moderately obese men and women1–3
Mario Kratz, Michael M Swarbrick, Holly S Callahan, Colleen C Matthys, Peter J Havel, and David S Weigle
ABSTRACT
Background: Recent studies indicated that dietary n–3 polyunsat-
urated fatty acids (PUFAs) increase circulating adiponectin concen-
trations in rodents.
Objective: We aimed to investigate whether a diet rich in n–3
PUFAs increased plasma concentrations of total or high-molecular-
weight (HMW) adiponectin in healthy overweight-to-moderately
obese men and women.
Design: Sixteen women and 10 men with a body mass index (in
kg/m2) between 28 and 33 were randomly assigned to consume a diet
rich in n–3 PUFAs (3.5% of energy intake) from both plant and
marine sources or a control diet (0.5% of energy intake from n–3
PUFAs). For the first 2 wk, these diets were consumed under isoca-
loric conditions; then followed a 12-wk period of ad libitum con-
sumption that was associated with a moderate loss of3.5% of body
weight in both groups. Total and HMW adiponectin plasma concen-
trations were measured before and after each diet phase.
Results: Plasma fasting adiponectin concentrations did not change
during the isocaloric period, but they increased modestly (10%)
during the ad libitum period when subjects lost weight [P0.009 for
time in repeated-measures analysis of variance] and to a similar
extent in subjects consuming the control  x  SD: 0.42  0.69
g/mL) and n–3 PUFA (0.45  0.85 g/mL) diets (P  0.920 for
time treatment interaction). Plasma concentrations of HMW adi-
ponectin did not change significantly during the study.
Conclusion: Dietary n–3 PUFAs consumed at levels of 3.5% of
energy intake do not significantly increase plasma or HMW adi-
ponectin concentrations in overweight-to-moderately obese healthy
men and women over the course of 14 wk. Am J Clin Nutr 2008;
87:347–53.
KEY WORDS Adiponectin, fatty acids, omega-3, n–3, diet,
obesity, overweight, humans
INTRODUCTION
The hormone adiponectin is specifically and abundantly se-
creted by adipocytes (1, 2). Adiponectin is present in plasma in
the form of low-molecular-weight trimers, mid-molecular-
weight hexamers, and high-molecular-weight (HMW) 12- or
18-mers (1). Although adiponectin is secreted by mature adipo-
cytes, plasma adiponectin concentrations show a negative cor-
relation with body fat mass (3). Adiponectin receptors are ubiq-
uitously expressed, and they appear most abundantly in liver and
muscle (4). The binding of adiponectin to its receptor has been
shown to induce fatty acid -oxidation and to increase cellular
insulin sensitivity (4). Consistent with this finding, plasma adi-
ponectin concentrations have been found to be positively asso-
ciated with systemic insulin sensitivity and to be reduced in states
characterized by insulin resistance, such as obesity (4). Further-
more, adiponectin exhibits protective properties with regard to
cardiovascular disease, and a low plasma adiponectin concen-
tration has been shown to be an independent risk factor for cor-
onary heart disease and hypertension (5). Factors associated with
elevated plasma concentrations of adiponectin include treatment
with thiazolidinediones, a class of drugs that act as ligands of the
transcription factor peroxisome proliferator–activated receptor
(PPAR) (6); moderate alcohol intake (7, 8); and marked weight
loss such as that associated with gastric bypass surgery (9, 10).
In the past few years, it has been reported that the feeding of
diets containing large amounts of fish oil increases plasma adi-
ponectin concentrations in rats (11) and mice (12). Neschen et al
(12) showed that the expression of the adiponectin gene was
increased in epididymal but not subcutaneous fat in mice fed fish
oil, and their results indicated that the increase in plasma adi-
ponectin concentrations was likely mediated by the activation of
PPAR. The only identified natural ligand of PPAR is a deriv-
ative of the n–6 fatty acid linoleic acid (13, 14), which suggests
that the components in fish oil that are capable of raising adi-
ponectin production most likely are also fatty acids; potential
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candidates include fish oil–specific long-chain n–3 polyunsatu-
rated fatty acids (PUFAs).
It is not known whether a diet rich in fish oil or n–3 PUFAs
increases plasma adiponectin concentrations in humans. In the
only published study investigating this question in humans, there
was a trend toward modestly (7.6%) higher plasma adiponectin
concentrations (P  0.086) when nonobese, weight-stable,
healthy men and women consumed a portion of fatty salmon
daily for 4 wk than was seen when they consumed a diet not
containing fish (15). From this study, it remained unclear, how-
ever, whether the trend may have been a result of increased n–3
PUFA intake or of changes in other dietary variables associated
with fish consumption, such as a higher protein intake. The
objective of the present study was to determine whether plasma
adiponectin concentrations are altered in overweight-to-
moderately obese healthy men and women during consumption
of a diet enriched in n–3 PUFAs or a control diet. Subjects were
assessed after both isocaloric dietary intake resulting in stable
body weight and ad libitum intake resulting in a modest loss of
body weight. We measured total adiponectin and HMW adi-
ponectin because the amount or the proportion of HMW adi-
ponectin relative to total adiponectin in plasma has been pro-
posed to be more closely associated with enhanced insulin
sensitivity than are total adiponectin concentrations (10, 16). We
also analyzed whether the concentrations of adiponectin at the
previously reported diurnal peak (ie, at 1000) and diurnal nadir
(ie, at 0400) (17) were altered during the control or n–3 PUFA
diets.
SUBJECTS AND METHODS
Subjects
The primary aim of this study was to test the hypothesis that a
diet rich in n–3 PUFAs lowers body weight in overweight and
moderately obese men and women. The sample size calculation
showed that, if 36 subjects completed the study, we would have
80% power to detect a 2.25-kg difference in body weight between
the control and n–3 PUFA groups at P 0.05. Using a sequential
clinical trial design, we performed one interim analysis after 26
subjects had completed the study. The result of this interim anal-
ysis was that we accepted the null hypothesis of no difference
between the groups and we stopped the study early on the
grounds of futility, because the 2 groups had very similar weight
loss. We here present plasma and HMW adiponectin data for
these 26 subjects throughout the study.
All 33 subjects entering the study had a body mass index (BMI:
in kg/m2) between 28 and 33; they were weight stable [2.27 kg
(5 pounds) in the past 6 mo] and were within 4.54 kg (10 pounds)
of their lifetime maximum weight. Exclusion criteria included
the use of tobacco or recreational drugs, alcohol abuse, a history
of cardiovascular disease or diabetes mellitus, the presence of
any chronic illness or psychiatric illness, restrictive eating be-
havior, pregnancy, and the intake of selective serotonin-reuptake
inhibitors, lipid-lowering drugs, -blockers, glucocorticoids, or
anabolic steroids. Three subjects withdrew because of dislike of
the study diet or because the required visits conflicted with their
work schedules. One subject failed to comply with the study diet
and was excluded after 8 wk. One subject was excluded because
fasting glucose concentrations measured at the end of the study
suggested that she had overt type 2 diabetes mellitus throughout
the study. Two subjects admitted to having started smoking dur-
ing the study and were therefore excluded. Plasma concentra-
tions of adiponectin were measured in the 26 remaining subjects
(16 F, 10 M). We used a block randomization procedure, sepa-
rately for men and women, to randomly assign the subjects. Of
the 26 subjects included in this analysis, 13 received the diet
enriched in n–3 PUFAs, and 13 received the control diet. Base-
line characteristics are shown, separately for the 2 diet groups, in
Table 1.
All subjects provided written informed consent. All proce-
dures were approved by the University of Washington Human
Subjects Committee.
Study design
In the 2-wk lead-in period, all subjects first consumed the
control diet, which was rich in monounsaturated fatty acids (Ta-
ble 2). The caloric content of the diet was calculated, on the basis
of a 3-d diet record completed by the subjects and the use of the
Mifflin formula (18), to maintain each subject’s weight within 1
kg of baseline. The control diet consisted of conventional foods
typically found in a mixed American diet. The principal sources
of fat during this period were high-oleic safflower and sunflower
oils and margarines based on these oils. The plant oils and the
margarines were used for the preparation of all meals and snacks.
In addition, subjects were given capsules containing high-oleic
safflower oil. Subjects were instructed to consume all food pro-
vided, not to eat any additional food, to take a specific number of
the oil capsules each day, and to complete a daily diary of food
intake. Subjects were asked to come in twice a week to be
weighed and to pick up food. Adjustments in the caloric content
of the diet were made as required to meet the target for weight
stability. On the morning of day 14 of the control diet and after an
overnight fast, subjects were admitted to the University of Wash-
ington General Clinical Research Center (CRC) for visit #1
(CRC1).
On completion of CRC1, subjects were randomly assigned to
1 of 2 groups: for 2 more wk, one of these groups continued to
consume the control diet, and the other group received the diet
enriched in n–3 PUFA (Table 2). All food was provided to the
subjects. The n–3 PUFA diet was identical to the control diet in
TABLE 1
Baseline characteristics of participants1
Control group
(n 13)
n–3 PUFA group
(n 13)
F/M 8/5 8/5
Age (y) 37.8 13.62 37.5 14.0
Body weight (kg) 85.4 9.3 87.6 12.9
BMI (kg/m2) 30.1 1.1 30.5 1.6
Fasting plasma glucose (mg/dL) 97 7 97 9
Fasting plasma insulin (U/mL) 13.7 6.0 28.9 44.6
Fasting plasma adiponectin (g/mL) 4.33 1.90 4.21 2.02
Fasting plasma HMW adiponectin
(g/mL)
1.89 1.33 1.85 1.24
HMW/total adiponectin ratio in
fasting plasma
0.40 0.13 0.41 0.18
1 PUFA, polyunsaturated fatty acids; HMW, high-molecular-weight.
The 2 groups did not differ significantly with regard to any of these variables
(in independent-sample t tests or Mann-Whitney U tests).
2 x  SD (all such values).
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all respects except the principal sources of dietary fat, in that
canola and flaxseed oils were substituted for high-oleic safflower
and sunflower oils. Both canola and flaxseed oils are rich in the
n–3 PUFA -linolenic acid. In addition, margarine rich in
-linolenic acid was provided. Subjects in the n–3 PUFA group
were asked to take a certain number of capsules containing fish
oil, instead of capsules containing high-oleic safflower oil. The
number of fish-oil capsules that subjects were asked to take was
calculated to provide 1.4% of energy in the form of long-chain
n–3 PUFA. At a total daily food intake of 1800 kcal, subjects
were asked to take 12 capsules, each containing 725 mg fish oil
or 240 mg long-chain n–3 PUFA. Subjects continued to pick up
food, to be weighed, and to turn in food records twice a week. The
total caloric content of dispensed food items was identical (iso-
caloric) to the amount that led to weight stability in the lead-in
diet period. The subjects were again instructed to consume all of
the food and not to eat any other food. On day 14 of this period,
subjects were readmitted to the CRC for visit #2 (CRC2).
After CRC2, subjects continued for another 12 wk to consume
the diets to which they had been randomly assigned. All food was
provided. Subjects continued to pick up food and to be weighed
twice a week. The amount of food provided during this period
was 115% of the amount provided in the previous 2 diet periods.
Subjects were specifically instructed to eat only when they were
hungry, to eat only as much as they needed to feel comfortably
satiated (ie, ad libitum), and to return any foods not eaten. These
returned foods were weighed to assess the amount consumed by
each subject on each day of the study. During this period, as an
approach to increase compliance with the study diet, subjects
were allowed to exchange one study meal/wk for a meal of
personal choice and to have 3 alcoholic beverages/wk. Sub-
jects were asked to provide accurate information on the type and
amount of alcoholic beverages consumed and of the food eaten
during the meal of personal choice. On day 84 of this diet period,
subjects were readmitted to the CRC for visit #3 (CRC3).
During each of the 3 admissions to the CRC, subjects were
weighed while wearing a hospital gown. Breakfast, lunch, din-
ner, and a snack were served at 0800, 1200, 1730, and 2000,
respectively, and subjects were asked to complete each meal
within 30 min. An intravenous line placed in the forearm was
used to sample 5 mL blood every half-hour between 0800 and
2100 and every hour between 2100 and 0800 the next morning.
We created a “pool” sample by combining 50 L plasma from
each sample drawn at 30-min intervals and 100 L plasma from
each sample drawn at 1-h intervals. Additional fasting blood
samples were drawn at 0800 on day 2 of each CRC visit. Blood
samples were placed on ice and centrifuged (15 min, 1600 g,
4 °C) immediately after the fasting blood draws had been com-
pleted. Plasma was kept frozen at 70 °C until analyses were
conducted. During CRC1 and CRC3, we also performed a
whole-body dual-energy X-ray absorptiometry scan with the use
of a GE Lunar Prodigy scanner (General Electric Healthcare,
Waukesha, WI) to assess body fat mass.
Laboratory methods
We measured total adiponectin concentrations in fasting
plasma samples and in samples that were pooled from the 38
samples drawn throughout each 24-h visit to the University of
Washington CRC (the pool sample). HMW adiponectin concen-
trations were measured in fasting samples only. We measured
total and HMW adiponectin concentrations in duplicate by using
a multimeric enzyme-linked immunosorbent assay (Alpco Di-
agnostics Inc, Salem, NH). This method has been validated
against Western blotting for measurement of adiponectin mul-
timers (19). Total adiponectin in fasting and pool samples also
was measured in duplicate with the use of a radioimmunoassay
(Linco Research Inc, St Charles, MO). In our hands, the Linco
radioimmunoassay kit yielded values for total adiponectin that
were much higher (2.5-fold) than the values obtained with the
Alpco enzyme-linked immunosorbent assay. However, the cor-
relation between the 2 methods was very high (r 0.94; 95% CI:
0.90, 0.96; P 0.0001), and in all cases, we took care to perform
repeated measurements on samples from the same subject within
the same assay run.
Fasting glucose was measured by using the hexokinase
method on a Hitachi 917 autoanalyzer (Roche Diagnostics,
Mannheim, Germany), and fasting insulin was measured with an
immunoassay on a different autoanalyzer (AIA 600 II; Tosoh
TABLE 2
Composition of the diets1
Lead-in period
(2 wk)
Isocaloric period
(2 wk)
Ad libitum period
(12 wk)
Control diet
(n 26)
Control diet
(n 13)
n–3 PUFA diet
(n 13)
Control diet
(n 13)
n–3 PUFA diet
(n 13)
Protein (% of energy) 15.9 0.1 15.9 0.0 15.8 0.1 15.8 0.5 16.0 0.4
Carbohydrates (% of energy) 49.8 0.4 49.8 0.2 49.5 0.2 49.5 1.0 49.4 1.4
Alcohol (% of energy) 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.7 0.7 1.1
Fat (% of energy) 34.3 0.4 34.3 0.2 34.7 0.1 34.0 0.8 33.9 0.8
SFA (% of energy) 8.6 0.1 8.5 0.1 8.4 0.0 8.5 0.3 8.4 0.3
MUFA (% of energy) 18.6 0.5 18.7 0.1 15.5 0.0 18.3 0.4 15.0 0.5
n–6 PUFA (% of energy) 4.8 0.0 4.8 0.0 4.9 0.0 4.8 0.2 4.8 0.1
n–3 PUFA (% of energy) 0.5 0.0 0.5 0.0 3.6 0.1 0.5 0.0 3.4 0.1
-Linolenic acid (% of energy) 0.5 0.0 0.5 0.0 2.2 0.0 0.5 0.0 2.0 0.1
Long-chain n–3 PUFA (% of energy) 0.0 0.0 0.0 0.0 1.4 0.1 0.0 0.0 1.4 0.1
Vitamin E (mg -TE/1000 kcal) 25.8 1.1 26.3 0.5 26.5 0.7 26.1 0.8 26.4 1.7
Cholesterol (mg/1000 kcal) 67.5 2.6 67.1 2.6 60.1 0.2 69.6 3.4 64.5 3.0
Fiber (g/1000 kcal) 11.1 0.1 11.0 0.1 11.1 0.0 10.7 0.8 10.6 0.4
1 All values are x SD. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; TE, tocopherol equivalents.
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Bioscience Inc, San Francisco, CA). Insulin resistance was mea-
sured by using homeostatic model assessment (HOMA) and cal-
culated as the product of the fasting plasma insulin concentra-
tions (in U/mL) and the fasting plasma glucose concentration
(in mmol/L), divided by 22.5.
Statistical analysis
All statistical analyses were performed with SPSS software
(version 11.5; SPSS Inc, Chicago, IL). Distribution of variables
was analyzed by checking histograms and normal plots of the
data, and normality was tested by means of Kolmogorov-
Smirnov and Shapiro-Wilk tests. Pearson correlation coeffi-
cients were calculated to investigate the association between the
change in body weight and plasma adiponectin, the association
between adiponectin concentrations in fasting and pool samples,
and the association between adiponectin plasma concentrations
and the HOMA insulin resistance (IR) index. Baseline charac-
teristics of the groups were compared by means of independent-
sample t tests or Mann-Whitney U tests. Changes in body weight,
body fat mass, total and HMW adiponectin concentrations, and
the ratio of HMW to total adiponectin were compared by using
repeated-measures analysis of variance (RM-ANOVA) with the
3 time points of the 3 visits (CRC1, CRC2, and CRC3) as the 3
levels of the within-subjects factor (time) and with treatment
(control versus n–3 PUFA) as the between-subjects factor. Post
hoc, we performed another RM-ANOVA with a reduced number
of levels of the within-subjects factor by including either just
CRC 1 and CRC2 or just CRC2 and CRC3. If the assumption of
sphericity did not hold, we used the Greenhouse-Geisser correc-
tion factor to adjust the df. The distribution of residuals of these
analyses was again tested by checking histograms and normal
plots of the data, and normality was tested by means of
Kolmogorov-Smirnov and Shapiro-Wilk tests. Friedman tests
were performed separately for each group if the residuals were
not normally distributed, which was the case for fasting plasma
insulin, HOMA, and total adiponectin data as measured by the
Linco radioimmunoassay kit. Friedman tests were followed up
with Wilcoxon’s signed-ranks tests after adjustment for multiple
testing. The level of significance was P 0.05.
RESULTS
Body weight changed significantly throughout the study (Ta-
ble 3), with no effect of treatment group on this change. During
the 2 wk of the isocaloric diet period when subjects were asked
to consume as many calories as they had required to be weight
stable in the lead-in period, body weight decreased by 0.4 kg.
Although this decrease was significant (post hoc RM-ANOVA
CRC1 compared with CRC2: P0.001 for time), it was minimal
(0.5% of body wt) and did not differ significantly between the
2 groups (P  0.538 for time  treatment). During the 12 wk
when subjects consumed these diets ad libitum, body weight
decreased by a mean of 3.1 3.8 kg in the control group and by
2.2 3.6 kg in the n–3 PUFA group. This change was significant
overall (post hoc RM-ANOVA CRC2 compared with CRC3: P
 0.001 for time) but did not differ significantly between the 2
groups (P  0.541 for time  treatment). Body fat mass de-
creased by 2.6 3.5 kg in the control group and by 1.8 2.9 kg
in the n–3 PUFA group, changes that were significant overall but
that did not differ significantly between treatment groups (P 
0.002 for time; P 0.583 for time treatment).
Total plasma adiponectin concentrations changed signifi-
cantly (P 0.011) over time, but there was no effect of treatment
group on this change (P  0.268). Post hoc RM-ANOVA
showed that plasma total adiponectin increased significantly dur-
ing the ad libitum period when subjects lost weight (CRC2 com-
pared with CRC3: P 0.009 for time) and that increases in the
control and n–3 PUFA groups did not differ significantly (P 
0.920 for time treatment).
The plasma concentrations of HMW adiponectin neither
changed significantly throughout the study (P 0.129 for time)
nor differed in any way between the 2 diet groups (P 0.497 for
TABLE 3
Body weight, body fat mass, fasting total and high-molecular-weight (HMW) adiponectin, and the ratio of HMW to total adiponectin during the study1
After the
lead-in period
(CRC1)
After the
isocaloric period
(CRC2)
After the
ad libitum period
(CRC3)
P2
Time
Time
treatment
Body weight (kg) 0.001 0.583
Control (n 13) 84.9 9.33 84.5 9.1 81.4 9.1
n–3 PUFA (n 13) 87.3 12.9 86.7 12.7 84.5 13.7
Body fat mass (kg) 0.002 0.583
Control (n 13) 31.5 4.8 — 28.9 6.5
n–3 PUFA (n 13) 33.9 5.6 — 32.0 4.9
Plasma total adiponectin (g/mL) 0.011 0.268
Control (n 13) 4.33 1.90 4.06 1.53 4.48 1.55
n–3 PUFA (n 13) 4.21 2.02 4.35 1.98 4.80 1.88
HMW adiponectin (g/mL) 0.129 0.497
Control (n 13) 1.89 1.33 1.92 1.36 2.01 1.38
n–3 PUFA (n 13) 1.85 1.24 2.08 1.24 2.16 1.27
HMW/total adiponectin 0.170 0.875
Control (n 13) 0.40 0.13 0.43 0.17 0.40 0.17
n–3 PUFA (n 13) 0.41 0.18 0.46 0.16 0.42 0.13
1 PUFA, polyunsaturated fatty acids; CRC1, CRC2, and CRC3, visits 1, 2, and 3 to the Clinical Research Center.
2 Repeated-measures ANOVA.
3 x  SD (all such values).
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time treatment). Similarly, the ratio of HMW to total adiponec-
tin did not change significantly (P  0.170 for time), and there
was no significant difference between the 2 treatment groups (P
 0.875 for time treatment).
Total adiponectin concentrations in the pool samples from
each 24-h stay in the CRC correlated highly with total fasting
adiponectin concentrations at CRC1 (r2  0.9216, P  0.001;
Figure 1), CRC2 (r2  0.897, P  0.001), and CRC3 (r2 
0.857, P  0.01). Changes throughout the study in total adi-
ponectin concentrations in these pool samples did not differ
significantly from those observed in fasting adiponectin, and,
therefore, they are not presented separately.
We also measured total adiponectin concentrations at 1000
and 0400 (on the next morning), the time points during the day on
which the adiponectin plasma concentration have been reported
to be highest and lowest, respectively (17). Because there were
again no differences between the control and n–3 PUFA groups
in any of these analyses, we pooled the data for this analysis.
Whereas plasma adiponectin concentrations at 1000 were sig-
nificantly greater during CRC3 than during CRC1 (P  0.051,
post hoc Wilcoxon’s test) or during CRC2 (P 0.030, post hoc
Wilcoxon’s test), we did not observe any difference in plasma
adiponectin at 0400 (P  0.572, Friedman test; Figure 2). It is
interesting that the significant difference in plasma adiponectin
concentrations between 1000 and 0400 that others previously
reported (17) was present in the current study only after subjects
had lost weight. Thus, the diurnal plasma adiponectin amplitude,
calculated as the difference between these time points, was sig-
nificantly greater at CRC3 (1.58  1.49 g/mL) than at CRC1
(0.46 1.22 g/mL; P 0.030, post hoc Wilcoxon’s test) or at
CRC2 (0.77  1.10 g/mL; P  0.021, post hoc Wilcoxon’s
test).
Despite the increase in total plasma adiponectin and the mod-
erate weight loss, we did not observe any change in fasting
glucose or insulin concentrations or in the HOMA-IR index
(Table 4). Moreover, we found no significant correlations be-
tween HOMA and total or HMW adiponectin, between HOMA
and the ratio of HMW to total adiponectin, or between changes in
HOMA and changes in total adiponectin, HMW adiponectin, the
ratio of HMW to total adiponectin, or the diurnal adiponectin
amplitude throughout the study. Two subjects in the n–3 PUFA
group had very high fasting insulin concentrations at baseline and
throughout the study. We therefore repeated all analyses involv-
ing insulin and the HOMA-IR index without these 2 subjects; the
results were identical to those obtained with these 2 subjects.
DISCUSSION
The major finding of this randomized, controlled, dietary in-
tervention study in overweight and moderately obese subjects
was that neither total nor HMW adiponectin concentrations dif-
fered significantly in any way between subjects consuming an
n–3 PUFA–enriched diet and control subjects consuming a diet
with low n–3 PUFA content. The finding that weight loss resulted
in the expected increase in adiponectin concentrations in both
subject groups (20, 21) validates our study design and the pre-
cision of the assays used. It is interesting that this effect of weight
loss was evident when we compared group means, whereas re-
gression analysis did not find a relation between the magnitude of
the increase of adiponectin and the degree of weight change in
individual subjects. A possible explanation for the latter obser-
vation is that the transition to a negative energy balance plays a
more important role than does the amount of fat lost in eliciting
adiponectin secretion from the adipocyte. This is certainly the
case for leptin, in that fasting causes a marked decline in plasma
leptin concentrations before significant loss of body fat mass (22,
23). Our group (24) previously observed that circulating adi-
ponectin concentrations do respond modestly to relatively acute
changes in energy balance but also that there are sex differences
in this response: the response is greater in women and less in men
during a 7-d period of marked restriction of energy intake. It also
may be that, with this small amount of weight loss, the changes
of weight do not closely represent the decreases of body fat
(particularly visceral fat mass and adipocyte size) that are likely
to be more important determinants of adiponectin production (2).
Leptin serves as an example of an adipokine that displays a
prominent diurnal pattern (25). Diurnal variation plays a key role
in the action of certain hormones, such as cortisol and the go-
nadotropins. This variation also has practical implications with
respect to the time at which plasma should be sampled to obtain
hormone measurements that reflect integrated 24-h plasma con-
centrations. Adiponectin has been reported to display a diurnal
rhythm in which the timing is inverse to that of leptin and in
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FIGURE 1. Relation between adiponectin concentrations in fasting
plasma and plasma pooled from the 38 samples that were collected in each
subject throughout the first 24-h Clinical Research Center visit #1 (CRC1),
measured with the use of a radioimmunoassay kit (Linco Research Inc, St
Charles, MO; n 26). The regression line was calculated with the use of the
following equation: y 0.8707x 0.3282 (r2 0.9216, P 0.001).
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FIGURE 2. Mean plasma total adiponectin concentrations throughout the
24-h span of each of the 3 Clinical Research Center visits (CRC1,; CRC2,
f; CRC3, ‚), measured with the use of a radioimmunoassay kit (Linco
Research Inc, St Charles, MO; n  26). Error bars represent SEs. For each
time point, the data were analyzed with the nonparametric Friedman test: *P
 0.05 for overall difference between the 3 CRC visits.
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which adiponectin has a lower amplitude (17). Our comparison
of plasma adiponectin concentrations at 1000 and 0400 showed
the emergence of such a rhythm with weight loss. Although we
did not find an association between the change in the diurnal
adiponectin amplitude and the HOMA-IR index in the present
study, it could be speculated that an increase in amplitude may
play an important role in the improvement of insulin sensitivity
that is seen when more insulin-resistant subjects lose body
weight. It is important to note that, although fasting insulin and
the HOMA-IR index appeared to improve in the n–3 PUFA
group, these changes were not significant and are explained
largely by the presence of the 2 subjects in that group who had
very high fasting insulin concentrations at baseline and through-
out the study. There was neither a consistent change in
HOMA-IR over time nor a correlation between the small increase
in adiponectin seen with weight loss and changes in fasting
insulin or HOMA-IR. The observed increase in plasma adi-
ponectin concentrations in the present study probably was too
small to induce improvements in insulin sensitivity in subjects
with mostly normal insulin sensitivity and normal glucose tol-
erance. The close correlation between total adiponectin mea-
sured in the fasting and the pooled 24-h plasma samples suggests
that a single fasting measurement provides a reliable estimate of
diurnal adiponectin concentrations over the course of a 24-h
period.
In the present study, subjects in the n–3 PUFA group con-
sumed 1.4% of total daily energy intake in the form of long-chain
n–3 PUFA of marine origin, which required them to take 12–24
capsules containing 725 mg fish oil each day. This dose is
roughly equivalent to the amount of n–3 PUFA in a daily portion
of 125–250 g fatty fish, such as Chinook salmon, and is on the
high end of what humans can be expected to consume. Neschen
et al (12) fed mice diets in which 4.4%, 8.1%, and 15% of the total
energy intake was in the form of long-chain n–3 PUFA, and they
observed marked increases in plasma adiponectin concentrations
with all 3 diets. Rossi et al (11) fed rats diets in which 16.2% of
total energy intake was in the form of cod liver oil—an amount
equivalent to5–6% of energy intake in the form of long-chain
n–3 PUFA. Although the possibility cannot be excluded, our
results do not suggest that higher doses of long-chain n3 PUFA
would have led to an increase in plasma adiponectin concentra-
tions, because there was no trend toward higher adiponectin
concentrations in subjects consuming the n–3 PUFA–rich diet
than in subjects consuming the control diet. It would be imprac-
tical for humans to achieve n–3 PUFA intakes much higher than
those in this study, even when ingesting substantial amounts of
supplements such as fish-oil capsules.
Lara et al (15) observed a trend toward moderately (7.6%)
higher plasma total adiponectin concentrations when subjects
consumed a daily portion of fatty salmon providing 2.4 g long-
chain n–3 PUFAs—equivalent to 1.1% of total energy in-
take—for 4 wk than when subjects did not consume any fish
(control diet period). The study of Lara et al was not randomized,
however; all subjects consumed the salmon diet first and then the
control diet. Moreover, the study was not well controlled, in that
only salmon was provided, and subjects chose all other food
items freely. Subjects were asked to replace the salmon with
turkey, chicken, cheese, or meat during the no-fish period, and
these choices probably resulted in differences in the amount of
n–3 PUFA, as well as in other factors such as protein or saturated
fat content. Unfortunately, the composition of the control diet
was not reported by Lara et al. Their report therefore left unclear
to what the modest differences in plasma adiponectin could be
attributed.
Neschen et al (12) presented evidence that fish-oil feeding
increasedadipocyteadiponectinexpressionandplasmaadiponectin
concentrations in mice through a mechanism involving the tran-
scription factor PPAR. This finding is consistent with the obser-
vation that treatment with a synthetic PPAR ligand, such as the
thiazolidinedione class of drugs, increases plasma adiponectin con-
centrations (6). The only natural ligand of PPAR that has been
TABLE 4
Plasma fasting glucose and insulin concentrations and homeostasis model assessment (HOMA) of the insulin resistance index throughout the study1
After the lead-in
period (CRC1)
After the
isocaloric period
(CRC2)
After the
ad libitum period
(CRC3)
P
Time2
Time
treatment2 Time3
Fasting glucose (mg/dL) 0.249 0.239
Control (n 13) 97 74 96 8 96 7
n–3 PUFA (n 13) 97 9 100 6 96 14
Fasting insulin (U/mL)
Control (n 13) 13.7 6.0 17.2 10.7 19.0 15.3 0.926
13.5 (6.4–25.2)5 14.4 (5.3–44.7) 17.2 (4.8–56.3)
n–3 PUFA (n 13) 28.9 44.6 28.0 40.0 22.3 25.0 0.635
13.8 (7.8–162.7) 16.6 (4.7–156.5) 18.9 (7.5–101.3)
HOMA insulin resistance index
Control (n 13) 3.0 1.3 3.7 2.4 4.0 3.1 0.926
2.8 (1.3–5.3) 3.1 (1.1–10.0) 3.4 (1.1–11.9)
n–3 PUFA (n 13) 6.4 10.0 6.4 9.5 5.0 6.1 0.257
2.9 (1.7–35.8) 4.1 (1.0–36.9) 4.0 (1.0–24.3)
1 CRC1, CRC2, and CRC3, visits 1, 2, and 3 to the Clinical Research Center; PUFA, polyunsaturated fatty acids.
2 Repeated-measures ANOVA.
3 Friedman test.
4 x  SD (all such values).
5 Median; range in parentheses (all such values).
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identified is 15-deoxy-12,14-prostaglandin J2 (13, 14), a deriva-
tive of the n–6 PUFA arachidonic acid. It would therefore be plau-
sible to assume that, because prostaglandins can be generated from
the long-chain n–3 PUFA eicosapentaenoic acid as well, the dietary
content of long-chain n–3 PUFA could affect the expression of
PPAR-regulated genes such as adiponectin (26). Moreover, eico-
sapentaenoic acid has been found to increase the expression of
PPAR itself (27).Thefact thatwedidnot findaneffectofadiet rich
in n–3 PUFA on plasma adiponectin concentrations suggests either
that n–3 PUFA does not play a major role in PPAR activation in
humans or that the pathways regulating the intracellular trafficking
or processing of n–3 PUFA that may be necessary for efficient
PPAR binding differ in humans and rodents.
A potential limitation of the present study is the fact that it was
not designed and powered to detect a clinically significant dif-
ference in plasma adiponectin concentrations between the n–3
PUFA and control groups. However, whereas it is theoretically
possible that we missed an effect of n–3 PUFA on plasma adi-
ponectin concentrations because of a lack of power, that possi-
bility seems unlikely, because there was not even a trend toward
a difference between controls and n–3 PUFA subjects in plasma
adiponectin concentrations. We therefore conclude that n–3
PUFA supplementation at a relatively high level does not in-
crease circulating plasma total or HMW adiponectin concentra-
tions in overweight-to-moderately obese human subjects. It ap-
pears unlikely that increased adiponectin has a role in the
reported metabolic and cardiovascular effects of marine oils.
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